Peritoneal carcinomatosis (PC) arising from gastrointestinal cancer
|
|
- Robert Parsons
- 5 years ago
- Views:
Transcription
1 71 Curative Treatment of Peritoneal Carcinomatosis Arising from Colorectal Cancer by Complete Resection and Intraperitoneal Chemotherapy D. Elias, M.D. F. Blot, M.D. A. El Otmany, M.D. S. Antoun, M.D. P. Lasser, M.D. V. Boige, M.D. P. Rougier, M.D. M. Ducreux, M.D. Department of Oncological Surgery, Gustave Roussy Institute, Villejuif, France. BACKGROUND. Peritoneal carcinomatosis (PC) is fatal, despite standard systemic chemotherapy. A new approach that combines maximal surgery with maximal regional chemotherapy has potential to cure selected patients who have colorectal PC. The authors have reported the oncologic results of this combined treatment. METHODS. The authors performed a retrospective study of 64 patients who had PC arising from colorectal adenocarcinomas, 19 (29.6%) of whom also had other metastases. These patients were treated by complete resection of all detectable tumors and by a 5-day course of early intraperitoneal chemotherapy (EPIC) with mitomycin C, then by 5-fluorouracil (n 37), or by intraoperative intraperitoneal chemohyperthermia (IPCH) with mitomycin C, alone or combined with cisplatin (n 27), in 2 separate trials. In the trial of IPCH, aimed at selecting the most reliable procedure in terms of spatial diffusion and thermal homogeneity, the 27 patients were treated with 7 different procedures. The extent of PC was assessed precisely by using a peritoneal index. The median follow-up period for the entire patient population was 51.7 months. RESULTS. The postoperative mortality and morbidity rates were 9.3% and 54.6%, respectively. Most severe complications occurred in patients who required extensive cytoreductive surgery. Global and disease-free survival rates were respectively 60.1% and 54.7% at 2 years and were 27.4% and 18.4% at 5 years. Results were significantly better (P 0.04) when patients were metastasis-free (apart from PC) and when the peritoneal index was lower than 16 (P 0.005). IPCH seemed to be more effective than EPIC for treatment of PC. CONCLUSION. This treatment plan, which combined maximal surgery with maximal regional chemotherapy, cured approximately 25% of patients. This strategy was mainly applicable to patients with limited intraperitoneal cancer volume and no extraperitoneal involvement. IPCH proved to be more effective than EPIC but more difficult to use correctly. Future results should improve through routine use of the optimal hyperthermia procedure, with improvements in the composition of instillate, better patient selection, and the reduction in the rate of complications that occurs with physician experience. Cancer 2001;92: American Cancer Society. Supported in part by grants from the French Association for Research Against Cancer (Association Française de Recherche contre le Cancer [ARC]). Address for reprints: D. Elias, M.D., Département de Chirurgie Générale Carcinologique, Rue Camille Desmoulins, Villejuif cedex, France; Fax: (11) ; elias@igr.fr Received November 6, 2000; revision received February 14, 2001; accepted March 20, KEYWORDS: peritoneal carcinomatosis, colorectal cancer, intraperitoneal chemotherapy, hyperthermia, cytoreductive surgery, peritonectomy. Peritoneal carcinomatosis (PC) arising from gastrointestinal cancer is invariably fatal. In a recent prospective study, the mean and median overall survival times were 6.9 and 5.2 months in patients with colorectal primary tumors. 1 Information on the natural spread of gastrointestinal cancer has been published recently, 2 and a potentially curative approach to PC has been developed. 3 Intraperitoneal chemotherapy has the advantages of bathing the entire cavity and 2001 American Cancer Society
2 72 CANCER July 1, 2001 / Volume 92 / Number 1 FIGURE 1. Peritoneal index defining precisely the extent of the peritoneal carcinomatosis. 17 Each of the 13 regions are classified as follows: 0 if no tumor; 1 if 5 mm tumor; 2 if tumor; 3 if 5 cm tumor or confluence. [Reprinted with permission from]. permitting very high local drug concentrations to be reached. 3,4 However, it is ineffective when used alone, for the following reasons: 1) Cytotoxic agents only penetrate tumor nodules superficially, to a depth of less than 2 mm. 5,6 2) Tumor cells colonize injured surfaces rapidly and massively, 7 a phenomenon that cannot be prevented by irrigating the peritoneum. 8 3) Postoperative adhesions occur very rapidly, considerably reducing the efficacy of delayed postsurgical intraperitoneal chemotherapy by creating a sanctuary where implanted tumor cells capitalize on growth factors generated during the healing process. 10,11 In addition, they are inaccessible to systemic chemotherapy, because neovascularization has not yet occurred. Thus, intraperitoneal chemotherapy will be effective on PC after resection of tumor nodules exceeding 1 mm only if the procedure is performed very early after surgery, before adhesions emerge. 3 Chemotherapy can take the form of early postoperative intraperitoneal chemotherapy (EPIC) or intraoperative chemohyperthermia (IPCH). 4,5,12,13 However, even if the PC is cured, patients may develop extraperitoneal metastases. The aim of this study was to assess the oncologic results of this new approach based on a combination of maximal surgery with maximal regional chemotherapy in patients with colorectal PC. PATIENTS AND METHODS From January 1993 to December 1999, sixty-four patients with colorectal PC were treated curatively in our center. There were 27 men and 37 women, with a mean age of years (range, yrs). The PC arose from adenocarcinomas of the colon in 46 patients, the rectum in 9, and from mucinous adenocarcinomas of the appendix in 9 patients (Grade 3 pseudomyxomas with solid areas of cancer, necrosis, atypia, and high mitotic activity). Patients were enrolled in two prospective trials focusing on the treatment of PC arising from gastrointestinal carcinomas, malignant mesotheliomas, and sarcomas. The first trial was a Phase II study of EPIC (without hyperthermia), based on the initial schedule used by Sugarbaker 9 and consisting of mitomycin C on postoperative Day 1, and 5-fluorouracil during the next 4 days. 9 We have published the preliminary results of this study. 14 The second trial was a Phase I II study of IPCH aimed at establishing the most reliable technique to obtain complete spatial diffusion of the infusate and thermal homogeneity within the abdominal cavity; seven different procedures were tested before finding an acceptable one. 15 The two trials were pooled for this analysis. Patients with liver or lymph nodes metastases in addition to PC were not treated with this protocol unless all distant sites of involvement were considered amenable to resection. Patients with computed tomography findings of lung metastases or invaded lymph nodes along the aorta or vena cava were not treated. Treatment combined maximal surgery and immediate maximal regional chemotherapy. Surgery Complete resection (or electrocauterisation) 16 of all macroscopically visible lesions of PC was required before intraperitoneal chemotherapy. If complete resection (residual tumor 1 mm in diameter) was not possible or would have resulted in extensive bowel resection necessitating permanent total parenteral nutrition, the procedure was contraindicated and the laparotomy was closed. Of course, peritonectomy was performed only on sites with tumor deposits. The normal peritoneum was left in place. The extent of PC was scored using the peritoneal index described by Sugarbaker. 17 Briefly, the abdominal cavity was divided into 13 regions (Fig.1), each assigned a score
3 Curative Treatment of Colorectal Peritoneal Carcinomatosis//Elias et al. 73 TABLE 1 Different IPCH Procedures Performed Successively during the Trial, Which Aimed to Select the Best Technical Procedure a N o No. of cases Type of circuit Drugs Cause of stop 1 5 Complete closure of the wound, 1 circuit 4 drains Y connections Mito: 10 mg/l Thermal inhomogeneity 2 b 7 Peritoneal cavity expander, same as above Mito: 10 mg/l Parietal wound recurrences 3 4 Only skin closure, double circuit, 4 drains without Y connections, with maximum tolerable volume Mito: 5 mg/l No volumetric standardization 4 5 Same as above, but standard volume of 3.5 L/m 2 Mito: 5 mg/l Same as above Mito: 10 mg/l then 8 mg/l 6 4 Same as above blue staining of the instillate Mito: 8 mg/l No complete blue staining 7 b 6 c Open wound, traction of skin upwards, double circuit, 2 L/m 2 blue staining of the instillate Mito: 20 mg/m 2 Cisplat: 200 mg/m 2 a Only 27 patients of this trial had colorectal cancers; 9 patients had another type of tumor. b Procedures performed with an open cavity. c This procedure was selected because it allowed complete bating of the abdominal cavity and good thermal homogeneity. from 0 3 according to the size and extent of tumor implants (total score 1 39). It is important to underline that very large and diffuse PCs were resected during the first 3 years of these trials (14 patients had a peritoneal index exceeding 25, with a maximum of 34). EPIC and IPCH The chemotherapeutic regimens and the volume of instillate were based on body surface area, resulting in similar drug concentrations in all the patients. EPIC began as soon as the wound was closed. This therapy was based on mitomycin C (10 g/m 2 ) on Day 1 and on 5-fluorouracyl (500 mg/m 2 )in1l/m 2 of Ringer lactate solution from Day 2 to Day 6. Each infusion lasted 23 hours, and the instillate was removed with drains over the next hour. IPCH was performed intraoperatively and involved seven successive techniques. At least four patients were treated with each technique before changing to the next technique if a techique proved unsatisfactory. A continuous closed-circuit was used, with six thermal probes placed inside the peritoneal cavity. Blue-stained instillate was used in the two last groups of procedures to assess the distribution of the liquid. 15 We successively used complete and permanent closure of the abdomen, an open technique with a peritoneal cavity expander, a closure of the skin alone (followed by reopening of the cavity, visceral suturing, and wound closure), and an open procedure, without an expander, the skin being pulled upwards with a specific retractor (Table 1). 15 The first 21 patients were treated with mitomycin C alone (5, 8, or 10 mg/l, in 3.5 L/m 2 ), and the other 6 patients received mitomycin C (20 mg/m 2 ) plus cisplatin (200 mg/m 2 )in 2.5 L/m 2 of perfusate. IPCH lasted 1 hour, at a peritoneal temperature of between 41 C and 44 C. Even if the technique of IPCH changed during the study, with only 6 patients over 27 undergoing the best procedure, we decided to group the results of all patients who underwent IPCH. This forms the IPCH group. Data Analysis Data were recorded prospectively. No patient was lost to follow-up. The cutoff date for this analysis was June 15, The median follow-up was 51.7 months (range, mos). A Kaplan Meier survival curve was fitted to the data and a log-rank test was used to identify differences between curves. The difference was considered significant if P RESULTS Surgical Procedures The mean number of tumoral regions was ; the mean peritoneal index was ; the mean number of resected organs was ; the mean number of bowel anastomoses was ; (median, 2; range, 0 7); and the mean number of lateral bowel sutures was There were 14 (21.8%) total colectomies with resection of the upper part of the rectum, 29 (45.3%) anastomoses on the lower part of the rectum after rectal resection with the Douglas pouch, 9 urinary tract sutures, and 15 (23.4%) iatrogenic pleural breaches. The mean operating time was minutes (median, 440 min; range, min), and mean blood loss was ml (median, 800 ml; range, ml). In 19 (29.6%) patients, other metastases (liver 11, ovary 9, spleen 3) were resected at the same time, and positive lymph nodes were found on pathologic examination of resection specimens in 27 (42.1%) cases. Details of the procedures in the two groups (EPIC and IPCH) are
4 74 CANCER July 1, 2001 / Volume 92 / Number 1 TABLE 2 Intraoperative Characteristics of the 64 Patients Treated for Colorectal Peritoneal Carcinomatosis EPIC (n 37) IPCH (n 27) P Peritoneal index (mean SD) NS Invaded regions (mean SD) NS Resected organs (mean SD) NS Bowel anastomosis (mean SD) NS Low rectal anastomosis (%) 17 (45.9) 12 (44.4) NS Total colectomy (%) 6 (18.6) 8 (29.6) NS Diaphragmatic break (%) 7 (18.9) 8 (29.6) NS Visceral metastasis (%) 12 (32.4) 7 (25.9) NS Lymph node metastases (%) 20 (54) 7 (25.9) 0.01 Duration of surgery a (mean SD) NS Blood loss (ml) (mean SD) NS a SD: standard deviation; NS: nonsignificant. TABLE 3 Postoperative Mortality and Morbidity of the 64 Patients Treated for Colorectal Peritoneal Carcinomatosis FIGURE 2. Survival rates of patients treated with resection and EPIC or IPCH (n 64). EPIC (n 37) IPCH (n 27) P Death (%) 3 (8.1) 3 (11.1) NS Abdominal complication (%) 17 (45.9) 12 (44.4) NS Fistula 7 5 Abscess 5 3 Reoperation 10 8 Extraabdominal complication (%) 20 (54.1) 16 (59.2) NS Pulmonary 9 8 Aplastic 0 2 Miscellaneous 10 7 Food intolerance (in days) mean (range) 10 (6 35) 12 (7 62) NS Hospital stay (in days) mean (range) 25 (12 99) 30 (14 87) NS NS: nonsignificant. FIGURE 3. Overall survival rates according to the presence or not of associated metastases (P 0.04). reported in Table 2, together with the extent of resection. Postoperative Course Six (9.3%) patients died during the postoperative period, 3 after EPIC and 3 after IPCH. These 6 patients had major intraoperative risk factors (diffuse PC with peritoneal index 28 in 4 patients and associated right lobectomy of the liver in 1 of these 4), and 2 patients also had preoperative risk factors (obesity 134 kg, clotting factor deficit). Minor or major complications occurred in 42 (65.6%) patients (Table 3). There was no significant difference between EPIC and IPCH in regard to the rate of complications, which correlated with the peritoneal index (P 0.01). Intraabdominal complications occurred in 29 (45.3%) patients, with 12 gastrointestinal fistulae, 8 deep abscesses, and reoperation in 18 (28.1%) patients. Oral food intolerance lasted a median of 10 days after EPIC and 12 days after IPCH. Extraabdominal complications, mainly of a pulmonary nature, occurred in 36 (56.2%) patients. The median hospital stay was longer for IPCH (30 days) than for EPIC (25 days) patients. Survival Overall and disease-free survival rates among the entire population (Fig. 2) were respectively 60.1% and 54.7% at 2 years, 47.1% and 39.4% at 3 years, 36% and 30.1% at 4 years, and 27.4% and 18.4% at 5 years (median survival time, mos). The presence of associated metastases had a significantly (P 0.04) negative influence on survival (Fig. 3), with 3-year overall and disease-free survival rates of 54.9% and 25.1%, respectively. The presence of involved lymph nodes in resected tissues did not affect survival (P 0.14). The peritoneal index, based on an arbitrary
5 Curative Treatment of Colorectal Peritoneal Carcinomatosis//Elias et al. 75 FIGURE 4. Overall survival rates according to the peritoneal index (P 0.019). FIGURE 5. Overall survival rates according to the type of intraperitoneal chemotherapy (P 0.13). cutoff of 15 (yielding similar numbers of patients in the 2 groups), had a major impact on survival (P 0.01) (Fig.4), with 3-year survival rates of 60.3% and 32.5%, respectively, among patients with values below and above this cutoff. Among the 14 patients with a peritoneal index exceeding 25, only 2 were alive and only 1 was disease-free after 49 months of follow-up. Survival rates were lower in the EPIC group than in the IPCH group (Fig. 5), but not significantly (P 0.13). Recurrences After a median follow-up of 51.6 months, cancer recurrence was detected in 42 (65.6%) patients. No peritoneal recurrence was detected in half of these 42 patients. Thus, only 21 (31.3%) patients had peritoneal recurrences. DISCUSSION These results confirm the efficacy of a curative approach to peritoneal carcinomatosis based on maximal surgery plus immediate maximal regional chemotherapy, according to the therapeutic principle described by Sugarbaker et al. 3 Several recent trials of intraperitoneal chemotherapy without preliminary maximal cytoreductive surgery have shown a 5-year survival rate of 0%. 18,19 The study by Eilber et al., 20 involving resection of recurrent abdominal sarcomas and delayed intraperitoneal mitoxantrone instillation, showed that postoperative adhesions prevented complete bathing of the peritoneal cavity and that subsequent recurrent peritoneal disease was located in drug no go areas rather than in blue-stained areas of loculated mitoxantrone. Likewise, in our study of IPCH, blue staining of the instillate showed that abdominal closure prevented complete bathing of the cavity 15 as areas behind the liver and stomach and at the root of the mesenterium frequently were not stained. This is probably one reason for the superior efficacy of IPCH over EPIC. The only survival rates so far published are those of Sugarbaker et al. 18 concerning colorectal patients with colorectal PC treated by resection and EPIC. In this latter series of 64 patients, the 5-year survival rate was close to 20% in the overall population, compared with 0% in the 28 patients with incomplete cytoreduction and 37% in the 36 patients with complete cytoreduction. Our 5-year survival rate was 27.4% among the 64 patients with complete cytoreductive surgery, despite the higher frequency of other metastases, which had a significantly deleterious impact on survival (Fig. 3). In our previous study of 22 patients with moderate PC and liver metastases, only the 3 patients with a single liver metastasis were free of disease at 24, 27, and 46 months after this new approach. 21 Like Sugarbaker s research group, we found no prognostic impact from invaded lymph nodes. In contrast, the extent of PC before resection had a major prognostic influence (Fig.4). Early in this study, we treated cases of massive diffuse PC, but we subsequently excluded such patients because of their high complication rate and poor survival. The peritoneal index is very useful for evaluating the precise extent of PC and for comparing the results of different series. Currently, we are unable to define a cutoff value above which this combined approach is not indicated for colorectal cancer, but it appears to be between 20 and 25. In our study, the oncologic results of IPCH were apparently better than those of EPIC (Fig.5), although the difference was not significant because of an inadequate number of patients and because only 6 patients in the EPIC group were treated with the optimal
6 76 CANCER July 1, 2001 / Volume 92 / Number 1 hyperthermia procedure. Although this was not a randomized comparison of the two procedures, it is noteworthy that the 2 groups of patients were comparable (Table 1). The superiority of IPCH seems to be due to the complete bathing of all at-risk surfaces of the abdominal cavity in the intraoperative open-cavity technique, 15 and the drug potentiation by hyperthermia. 4,5,12,13 The main advantage of EPIC is its simplicity. In our opinion, EPIC is preferable to no treatment and to poorly performed IPCH. The postoperative mortality and morbidity rates were high in this study, and mainly they were attributed to patients who underwent extensive cytoreductive surgery for massive diffuse PC. However, we recently performed a pharmacokinetic study of IPCH with oxaliplatin in 22 patients and observed no postoperative deaths and only two gastrointestinal fistulae. The complication rate fell with experience. We think that a five-day course of EPIC, with gastrointestinal sutures floating in the chemotherapy solution, is more dangerous than IPCH alone. Future results with IPCH should improve through routine use of the optimum hyperthermia procedure identified here, through improvements in the composition of the instillate, and through better patient selection. This new combined curative approach to PC is indicated only for selected patients with moderate or minimal PC and with no distant metastases. We currently are able to cure more than 25% of such patients with PC arising from colorectal cancer, which is incurable by standard systemic chemotherapy. However, in the last 2 years, rare patients who have undergone resection of the primary and 1 5 small deposits of PC followed by the most recent systemic chemotherapy (including oxaliplatin or irinotecan) have not had a recurrence in the peritoneum (negative second-look laparotomy performed 8 10 mos latter). These findings provide justification for a randomized trial that compares treatment by complete resection of PC followed by IPCH plus systemic chemotherapy with treatment by complete resection plus systemic chemotherapy alone. REFERENCES 1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: resuts of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88: Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996;82: Sugarbaker PH, Cuniffe W, Belliveau JF, de Bruin E, Graves T. Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1988;1: Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994;41: Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990;26: Didkhoff T, van der Heider J, Dubbelman R, ten Bokkel Huinink WW. Tissue concentration of platinum after intraperitoneal cisplatin administration in patients. Proc AACR 1985;26: Zoetmulder FA. Cancer cell seeding during abdominal surgery: experimental studies. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer, 1996: Sweitzer KL, Nathanson SD, Nelson LT, Zachary C. Irrigation does not dislodge or destroy tumor cells adherent to the tumor bed. J Surg Oncol 1993;53: Sugarbaker PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994;37:(2 Suppl):S Jacquet P, Elias D, Sugarbaker PH. [Tumor implantation in cicatrization sites following surgery for digestive cancers]. J Chir (Paris) 1996;133: Murakami A, Koga S, Maeta M. Thermochemosensitivity: augmentation by hyperthermia of cytotoxicity of anticancer drugs against human colorectal cancer, measured by the human tumor clonogenic assay. Oncology 1988;45: Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39(6 Pt 2): Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomosis in the rat. Br J Surg 1991;78: Elias D, Dubé P, Blot F, Bonvallot S, Eggenspieler P, Sabourin JC, et al. Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. Eur J Surg Oncol 1997;23: Elias D, Antoun S, Goharin A, El Otmany A, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique for treatment of peritoneal carcinomatosis after complete resection. Int J Surg Invest 2000;1: Sugarbaker PH. Dissection by electrocautery with a ball tip. J Surg Oncol 1994;56: Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14: Sugarbaker PH, Schellinx ME, Chang D, Koslowe P, von Meyerfeldt M. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996; 20:585 91; discussion Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88: Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6: Elias D, Goharin A, El Otmany A, Bonvallot S, Meshaka P, Attalah D, et al. Treatment of liver metastases associated with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate intraperitoneal chemotherapy: results in 22 cases. Int J Surg Invest 2001 (in publication).
Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective
More informationCurative treatment of colorectal peritoneal carcinomatosis: Current status and future trends
Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends Léon Maggiori, Dominique Elias To cite this version: Léon Maggiori, Dominique Elias. Curative treatment of colorectal
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationResults of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationDepartment of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationReview of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis
Jpn J Clin Oncol 2001;31(12)573 583 Special Article Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis Paul H. Sugarbaker Washington Cancer Institute, Washington, DC,
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 16 AUGUST 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal
More informationPeritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Department of surgical oncology, Carl von Hess hospital, Hammelburg, Germany www.klinik-hammelburg.de
More informationCURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationCytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
More informationA new scoring system for peritoneal metastasis in gastric cancer
Gastric Cancer (2003) 6: 146 152 DOI 10.1007/s10120-003-0243-6 2003 by International and Japanese Gastric Cancer Associations Original article A new scoring system for peritoneal metastasis in gastric
More informationHeated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitonealchemotherapy-hipec-for-advanced-abdominal-cancers/7091/
More informationRationale for the treatment. Peritoneal Surface Malignancy
Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationPlanned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei
More informationVic J. Verwaal, MD, PhD, 1 Sjoerd Bruin, MD, 1 Henk Boot, MD, PhD, 2 Gooike van Slooten, MD, 1 and Harm van Tinteren, ScM 3
Annals of Surgical Oncology 15(9):2426 2432 DOI: 10.1245/s10434-008-9966-2 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy
More informationClinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results
International Scholarly Research Network ISRN Surgery Volume 2011, Article ID 529876, 6 pages doi:10.5402/2011/529876 Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced
More informationManagement of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
More informationCRS e HIPEC: Efficacia e Limiti
CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationORIGINAL ARTICLE. Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer
ORIGINAL ARTICLE Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer O. Glehen, MD; V. Schreiber, MD; E. Cotte, MD; A. C. Sayag-Beaujard,
More information1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
More informationSurgical Department, Didimotichon General Hospital, Didimotichon, Greece 2
Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy
More informationUsing Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
72 Current Drug Discovery Technologies, 2009, 6, 72-81 Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy Kurt Van der Speeten 1, Oswald Anthony Stuart
More informationKey words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy.
EJSO 2001; 27: 286 290 doi:10.1053/ejso.2000.1095, available online at http://www.idealibrary.com on Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy
More informationHepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationClinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
More informationCRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
More informationPERITONEAL CARCINOMATOSIS (PC) of colorectal origin
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer By Vic
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
More informationCRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
More informationPseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy D. Elias, F. Gilly, F. Quenet, Jm. Bereder, L. Sideris, B. Mansvelt,
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationCost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer
Volume 11 Number 3 2008 VALUE IN HEALTH Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer Julia Bonastre PhD 1 Julie Chevalier
More informationORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric,
More informationORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:1575 1581 DOI 10.1245/s10434-011-1631-5 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients
More informationCytoreduction including total gastrectomy for pseudomyxoma peritonei
Original article Cytoreduction including total gastrectomy for pseudomyxoma peritonei P. H. Sugarbaker Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA Correspondence to: Dr
More informationA Case Report of Surgical Resections with Local and Systemic Chemotherapy for Three Recurrences of Colon Cancer Occurring Ten Years after Colectomy
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis
JBUON 2017; 22(6): 1547-1553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, pancreatic ductal, laparoscopic distal pancreatectomy for, 61 Adrenal cortical carcinoma, laparoscopic adrenalectomy for, 114
More informationCurrent standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials
Current standard in treatment of peritoneal carcinomotisis Data behind the HIPEC trials Overview Peritoneal carcinomatosis STANDARD treatment HIPEC Results of treatment Counter side of treatment Peritoneal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationCytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Ann Surg Oncol (2013) 20:4224 4230 DOI 10.1245/s10434-013-3145-9 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationAscites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
The American Journal of Surgery (2013) 205, 668-673 Clinical Surgery Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
More informationPseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
More informationInformation for health professionals - pseudomyxoma peritonei
Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive
More informationHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationMP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationCOLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
More informationMATERIALS AND METHODS Patients
Yonago Acta Medica 2017;60:174 178 Original Article Gross Appearance and Curability Are Predictive Factors of a Better Prognosis After Gastrectomy in Gastric Cancer Patients with Metastasis to the Adjacent
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationShort bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations
JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationINTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationColon Cancer Surgery
Colon Cancer Surgery Introduction Colon cancer is a life-threatening condition that affects thousands of people. Doctors usually recommend surgery for the removal of colon cancer. If your doctor recommends
More informationSpecialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management
More informationHow to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationClinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin
Gastroenterology Research and Practice Volume 2012, Article ID 981245, 5 pages doi:10.1155/2012/981245 Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma
More informationKathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationPeritoneal dissemination is a common manifestation of disease
ORIGINAL ARTICLE Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Dario Baratti, MD, Shigeki Kusamura,
More informationContents. Part 1. Peritoneal Carcinomatosis: Basic Concepts
Contents Part 1. Peritoneal Carcinomatosis: Basic Concepts 1. Structure and Function of Mesothelial Cells... 1 Introduction... 1 Structure of Mesothelial Cells... 1 Mesothelial Cell Functions... 3 Slippery
More informationAppendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
More informationNever mistake knowledge for wisdom. One helps you make a living; the other helps you make a life.
Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life. -Sandra Carey In honour of God and to my loving wife, Helena, and our children List of Papers This thesis
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
More informationThis is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
More informationPharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer
Online Submissions: http://www.wjgnet.com/1948-5204office wjgo@wjgnet.com doi:10.4251/wjgo.v2.i1.19 World J Gastrointest Oncol 2010 January 15; 2(1): 19-30 ISSN 1948-5204 (online) 2010 Baishideng. All
More informationDisseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case
Surg Today (2001) 31:646 650 Disseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case Yoshito Kuroki 1, Shunyou Otagiri 1, and Kazuhiro Tsukada 2 1 Department
More informationHyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer
Review Article Hyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer Pedro Bretcha-Boix, Jose Farre-Alegre USP Hospital San Jaime, Torrevieja, Spain Corresponding to: Pedro Bretcha-Boix,
More informationOvarian cancer: clinical practice the Arabic perspective
Lead Group Log Ovarian cancer: clinical practice the Arabic perspective Experience of Hôtel-Dieu de France University Hospital (Beirut, LEBANON) in supraradical surgery for ovarian cancer David ATALLAH
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationM of initial surgical treatment of cancer of
ATTEMPTED PALLIATION BY RADICAL SURGERY FOR PELVIC AND ABDOMINAL CARCINOMATOSIS PRIMARY IN THE OVARIES ALEXAXDER BRUNSCHWIG, M.D. UCH HAS been written about the results M of initial surgical treatment
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationSynchronous Hepatic Cryotherapy and Resection
HPB Surgery, 2000, Vol. 11, pp. 379-382 Reprints available directly from the publisher Photocopying permitted by license only (C) 2000 OPA (Overseas Publishers Association) N.V. Published by license under
More informationAbstract. Materials and methods
Int J Gynecol Cancer 2006, 16, 490 495 Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures A.-A.K. TENTES, C.G. MIRELIS, S.K. MARKAKIDIS,
More informationHyperthermic Intraperitoneal Chemotherapy
Hyperthermic Intraperitoneal Chemotherapy Acta chir belg, 2006, 106, 276-282 Surgery for Peritoneal Carcinomatosis from Colorectal Origin : Techniques and Limitations W. P. Ceelen Surgical Oncology, University
More informationSummary of the study protocol of the FLOT3-Study
Summary of the study protocol of the FLOT3-Study EudraCT no. 2007-005143-17 Protocol Code: S396 Title A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationSURGERY OF RECURRENCIES
La chirurgia Bergamo, delle 6 th May recidive 2011 SURGERY OF RECURRENCIES Pierluigi Benedetti Panici Calcagno Marco, Gasparri Maria Luisa, Domenici Lavinia, Bellati Filippo CANCRO EPITELIALE DELL OVAIO:
More informationOptimal drugs for HIPEC in different tumors
JBUON 2015; 20 (Suppl. 1): S40-S46 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Optimal drugs for HIPEC in different tumors Eelco de Bree Department
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More information